Clinical Trials Logo

Primary Ovarian Insufficiency clinical trials

View clinical trials related to Primary Ovarian Insufficiency.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06228547 Completed - Clinical trials for Premature Ovarian Insufficiency

Women's Experience of Premature Ovarian Insufficiency (POI) Diagnosis: Update on Actual Practices and Patient's Follow up

EMPOIHER
Start date: July 26, 2023
Phase:
Study type: Observational

Premature ovarian insufficiency (POI) affects 2,8 to 3,5% of women before the age of 40. Previous foreign studies revealed that only half of POI disclosures occurred during a medical consultation and that the diagnosis was often discussed in less than 5 minutes. As a result, most of patients felt a lack of information, and consequently sought data on the internet. None of these studies were conducted in France. The aim of this study is to analyze current practices related to POI diagnosis and to assess women's satisfaction

NCT ID: NCT05443282 Completed - Oxidative Stress Clinical Trials

Ovarian Reserve and Matrix Metalloproteinases

Start date: August 10, 2021
Phase:
Study type: Observational

Primary Ovarian Insufficiency (POI) is dysfunction of ovaries before 40 years of age. It has been reported that genetic factors, endocrine disorders, previous pelvic surgeries, chemotherapy and radiotherapy, and autoimmune mechanisms play a role in 10%, however the etiology has not been clarified in 90% of the cases. Oxidative stress and autoimmunity has been shown to be responsible in the etiopathogenesis of POI. Prolidase is an imidodipeptidase. Prolidase was shown to be related with oxidative stress and autoimmune diseases in previous studies. In addition, it is thought that the level of prolidase plays a role both in the etiopathogenesis and progression of diseases. This study aims to investigate the level of prolidase enzyme in women with POI.

NCT ID: NCT05310617 Completed - Infertility Clinical Trials

Parental Project and Premature Ovarian Insufficiency

ParentIOP
Start date: June 20, 2022
Phase:
Study type: Observational

One of the main repercussions of POI is infertility. When the diagnosis of POI is announced, the question of fertility is addressed and the patient is often directed towards egg donation or adoption when she has a parental project. However, there are cases of spontaneous pregnancies after diagnosis. This study was conducted to determine the proportion of patients with POI who were able to realize a parental project after diagnosis in the long term and by what means.

NCT ID: NCT05231980 Completed - Clinical trials for Polycystic Ovary Syndrome

Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate

Start date: June 5, 2022
Phase: Phase 2
Study type: Interventional

This study evaluate the addition of PTX and ALA to clomiphene citrate in the treatment of polycystic ovary.

NCT ID: NCT05138367 Completed - Clinical trials for Premature Ovarian Failure

Effects of UCA-PSCs in Women With POF

Start date: December 1, 2018
Phase: Phase 1
Study type: Interventional

This study was a single-center randomized controlled trial at the Affiliated Drum Tower Hospital of Nanjing University Medical School. There were patients who underwent clinical follow-ups since 2018 in POF clinic. Patients were given treatment of either UCA-PSC or WJ-MSC.

NCT ID: NCT04943354 Completed - Clinical trials for Cardiovascular Diseases

Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian Failure

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Research objective. - To study the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with non-communicable diseases and adverse outcomes in women with premature ovarian failure. Research objectives: - To study the associations between combinations of single-nucleotide polymorphisms and behavioural risk factors with heart rate disorders and adverse outcomes in women with premature ovarian failure - Examine the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with stable STIs in women with premature ovarian failure. - Examine the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with thrombomolia in women with premature ovarian failure - Study the associations between combinations of single nucleotide polymorphisms and behavioural risk factors and adverse cardiovascular outcomes in women with premature ovarian failure.

NCT ID: NCT04641624 Completed - Clinical trials for Premature Ovarian Insufficiency

sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency

POI&niacin
Start date: November 20, 2020
Phase:
Study type: Observational

Aim: To evaluate serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin levels in women with premature ovarian insufficiency (POI) and to compare the results with those of healthy subjects. Methods: This prospective study will be included 45 women with idiopathic premature ovarian insufficiency and 45 controls. The blood for analysis will be obtained at the early follicular phase of the menstrual cycle and serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin levels will be measured using a commercially available ELISA kit.

NCT ID: NCT04475744 Completed - Clinical trials for Premature Ovarian Insufficiency

4-step ASCOT in POI Women to Promote Follicular Rescue

Start date: March 5, 2021
Phase: Phase 3
Study type: Interventional

To promote follicular development in POI women, G-CSF mobilized activated platelet rich plasma will be directly injected into the ovarian medulla. This is a prospective, observational, multicentric, open, pilot-controlled randomized trial which seeks to evaluate the impact of the 4-step ASCOT technique on the ovarian reserve and reproductive outcomes of POI patients. The study will be developed in two phases. In a first step, POI women will randomized to control or undergo the 4-step ASCOT technique based on the direct ovarian injection of G-CSF mobilized and activated PRP. Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 3 month in the controls and for 6 months in the treated and COS initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.

NCT ID: NCT04237909 Completed - Clinical trials for Premature Ovarian Failure

Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency

Start date: January 27, 2020
Phase: N/A
Study type: Interventional

Reproductive age women diagnosed with poor ovarian response (POR) based on Poseidon criteria and premature ovarian insufficiency (POI) based on ESHRE criteria and with a history of at least one prior failed IVF cycle will be recruited for the study. Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle stimulating hormone (FSH) levels will determined at baseline. Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols and will be injected to at least one ovary. Ovarian reserve parameters and IVF outcomes will be determined.

NCT ID: NCT04163640 Completed - Infertility, Female Clinical Trials

Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response

Start date: February 24, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to perform a prospective randomized controlled trial seeking to characterize the effects of intra-ovarian injection of platelet rich plasma (PRP) on biomarkers of ovarian reserve as well as IVF outcomes in women with primary ovarian insufficiency (POI) and poor ovarian response (POR) who decline the use of an egg donor to establish a pregnancy.